The Alzheimer's Demonstration program was established in 1991 to develop models of home and community-based care for persons with Alzheimer's disease and their families. After more than ten years of program experience and evaluation, the Alzheimer's Demonstration program has generated significant information about how to work successfully with families coping with Alzheimer's disease. In particular, the Demonstration program has been very successful in developing innovative program models and approaches to serving traditionally underserved populations such as ethnic minorities, low income, and rural families. Of particular interest is the significant number of successful project components that are replicable in a variety of community settings. This article provides detailed programmatic and replication information for successful Alzheimer's Demonstration program models: Mobile Day Care Rural Geriatric Dementia Evaluation, El Portal services for Latino, Client Advocates, and AL-CARE services for clients who live alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1300/J027v21n03_08 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease.
J Appl Lab Med
January 2025
Eli Lilly and Company, Indianapolis, IN, United States.
Background: Blood-based biomarkers, especially P-tau217, have been gaining interest as diagnostic tools to measure Alzheimer disease (AD) pathology.
Methods: We developed a plasma P-tau217 chemiluminescent immunoassay using 4G10E2 and IBA493 as antibodies, a synthetic tau peptide as calibrator, and the Quanterix SP-X imager. Analytical validation performed in a College of American Pathologists-accredited CLIA laboratory involved multiple kit lots, operators, timepoints, and imagers.
Multiple-Signal Amplification Strategy to Fabricate an Ultrasensitive Electrochemiluminescence Magnetic Immunosensor for Detecting Biomarkers of Alzheimer's Disease via Iridium-Based Self-Enhancing Nanoemitters.
ACS Sens
January 2025
School of Chemistry and Life Sciences, Jiangsu Key Laboratory for Environmental Functional Materials, Suzhou University of Science and Technology, Suzhou, Jiangsu 215009, China.
Alzheimer's disease (AD) is characterized by progressive memory loss and cognitive decline, significantly impairing the daily life of elderly individuals. The low abundance of blood-based biomarkers in AD necessitates higher analytical technique requirements. Herein, one novel iridium-based ECL self-enhanced nanoemitter (TPrA@Ir-SiO) was unprecedentedly reported, and it was further used to construct an ultrasensitive ECL magnetic immunosensor by a multiple-signal amplification strategy to unequally sensitively and accurately detect the AD blood-based biomarker (P-tau181) in this work.
View Article and Find Full Text PDFImproving estimation efficiency for survival data analysis by integrating a coarsened time-to-event outcome from an external study.
Biometrics
January 2025
Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
In the era of big data, increasing availability of data makes combining different data sources to obtain more accurate estimations a popular topic. However, the development of data integration is often hindered by the heterogeneity in data forms across studies. In this paper, we focus on a case in survival analysis where we have primary study data with a continuous time-to-event outcome and complete covariate measurements, while the data from an external study contain an outcome observed at regular intervals, and only a subset of covariates is measured.
View Article and Find Full Text PDFAuranofin-loaded PLGA Nanoparticles for Neuroprotection against Aluminium-induced Alzheimer's Disease.
Curr Pharm Des
January 2025
Maharaja Ranjit Singh Punjab Technical University Pharma Innovation Lab, Department of Pharmaceutical Sciences & Technology Bathinda India.
Aim: The aim of the current study was to explore nano-formulation for effective neuroprotection by auranofin.
Background: Currently, the treatment options for various CNS disorders, particularly neurodegenerative disorders, are greatly constrained. A significant obstacle in this pursuit is the blood-brain barrier, a shielding covering that hinders the route of numerous biochemical treatments into the brain.
Xixin Decoction's novel mechanism for alleviating Alzheimer's disease cognitive dysfunction by modulating amyloid-β transport across the blood-brain barrier to reduce neuroinflammation.
Front Pharmacol
January 2025
Key Research Laboratory for Prevention and Treatment of Cerebrospinal diseases, Shaanxi Provincial Administration of Traditional Chinese Medicine, Xianyang, China.
Purpose: Xixin Decoction (XXD) is a classical formula that has been used to effectively treat dementia for over 300 years. Modern clinical studies have demonstrated its significant therapeutic effects in treating Alzheimer's disease (AD) without notable adverse reactions. Nevertheless, the specific mechanisms underlying its efficacy remain to be elucidated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!